09:16:12 EST Tue 07 Feb 2023
Enter Symbol
or Name

Login ID:
Innocan Pharma Corp
Symbol INNO
Shares Issued 221,297,497
Close 2021-06-11 C$ 0.51
Recent Sedar Documents

Innocan's LPT shows seven-week prolonged release of CBD

2021-06-11 06:34 ET - News Release

Ms. Iris Bincovich reports


Innocan Pharma Corp. has provided an update. A recent study conducted on mice has demonstrated a prolonged release of cannabidiol (CBD) into the animals' bloodstream for at least seven weeks following two local injections. Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when administered through traditional channels.

This study was led by Dr. Ahuva Cern, a senior researcher in the lab of Prof. Chezy Barenholz of the Hebrew University of Jerusalem, and is based on Innocan's licensed CBD-loaded liposome platform technology (LPT) for injectable CBD solutions.

"We are extremely satisfied with the initial results of this study, which shows significant improvement in administrating CBD through Innocan's LPT," said Prof. Barenholz. "Finding a remaining CBD in the injection site could indicate even a longer prolonged release of CBD into the bloodstream."

"This study marks another positive and exciting result in our ongoing injectable CBD research," stated Innocan chief executive officer Iris Bincovich. "These results may open the door to a wide range of exciting therapeutic possibilities, especially in treatment of conditions related to the central nervous system."

Innocan's relationship with the Hebrew University

Innocan Pharma Ltd., a wholly owned subsidiary of the company, has entered into a worldwide exclusive research and licence agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem, with respect to the design, preparation, characterization and evaluation of hydrogels containing CBD-loaded (or containing other cannabinoids) liposomes. The research and development initiative is led by Prof. Barenholz, head of the membrane and liposome research department at the Hebrew University, which is the inventor of over 55 patent families, two of which underlie Doxil, a Food and Drug Administration-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. A patent was filed covering this technology on Oct. 7, 2019.

About Innocan Pharma Corp.

Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells.

We seek Safe Harbor.

© 2023 Canjex Publishing Ltd. All rights reserved.